Rezera sets IPO terms to finance phase 3 testing of ruvonoflast in peripheral artery disease
Rezera is moving toward the public markets with a financing plan built around one asset: ruvonoflast, its brain-penetrant NLRP3 inhibitor. The Boston-based biotech is aiming to raise up to $181 million in an initial public offering that would fund a planned phase 3 trial in peripheral artery disease and carry the program toward a 2028 readout.
The offering includes 16.7 million shares priced between $11 and $13 apiece, with the potential for underwriters to purchase an additional 2.5 million shares. At the midpoint of the range, net proceeds would total about $181 million; if the full over-allotment option is exercised, that figure would rise to $208.9 million.
Rezera’s strategy is straightforward. It is placing a large bet on inflammation as a druggable driver of vascular disease, and it is choosing PAD because the condition combines high prevalence, persistent morbidity, and limited relief from standard cardiometabolic therapy.
Why peripheral artery disease became the lead indication
PAD is atherosclerotic cardiovascular disease of the limbs, typically caused by narrowed or blocked small arteries that restrict blood flow to the legs. In clinical practice, the disease often persists despite use of lipid-lowering agents, antihypertensive drugs, and diabetes therapies. Rezera’s filing frames that residual risk as an opening for a treatment that targets innate immune signaling rather than cholesterol alone.
The company’s rationale rests on the biology of the NLRP3 inflammasome, a central component of inflammatory signaling. Inhibition of this pathway is designed to blunt downstream cytokine activation and reduce the chronic inflammatory burden that contributes to vascular injury and plaque instability. In PAD, where ischemia and inflammation intersect, that mechanism is especially attractive because the disease is not driven by lipid excess alone; it is sustained by a broader inflammatory milieu that affects the arterial wall and the tissues downstream from it.
One sentence captures the commercial logic plainly: PAD is common, durable, and expensive to treat poorly.
Rezera estimates that roughly 20 million adults in the United States are affected by PAD, and it is targeting what it describes as a $5 billion market opportunity. The size of the population matters, but so does the clinical reality of the disorder. Patients can remain symptomatic, functionally limited, and exposed to ongoing cardiovascular risk even when conventional therapies are already in place.
Phase 2 inflammation data arrived from a different program
The company’s recent clinical signal came from a separate setting. Last month, Rezera reported phase 2 findings in obesity when ruvonoflast was combined with semaglutide, the active ingredient in Novo Nordisk’s Wegovy. In that study, the combination produced a statistically significant reduction in high-sensitivity C-reactive protein, or hsCRP, compared with semaglutide alone.
hsCRP is a circulating marker of systemic inflammation, and a drop in the biomarker fits the drug’s intended mechanism. The result does not establish cardiovascular efficacy in PAD, but it does provide biologic support for a program built on inflammation control. In atherosclerotic disease, dampening inflammatory signaling can be more than a laboratory exercise; it may translate into slower plaque progression, less endothelial activation, and less vulnerability to acute events. The clinical question now is whether that biomarker effect can be carried into a disease state where vascular obstruction directly limits limb perfusion.
Rezera had already decided to prioritize PAD by the time the obesity data were disclosed. That sequencing reveals how the company is thinking about development risk. Rather than leaning on a metabolic indication first, it is moving the asset into a cardiovascular population where the unmet need is sharper and the therapeutic hypothesis can be tested more directly against vascular disease biology.
Capital allocation now hinges on a single late-stage vascular program
The IPO filing makes clear where the money is expected to go first: advancing ruvonoflast through a planned phase 3 study in PAD next year. A late-stage cardiovascular trial demands substantial capital, and the company is structuring the offering around that need.
Rezera disclosed only $3.9 million in cash before the IPO proceeds, leaving little room for a broad portfolio approach. The filing also softened earlier language about using offering proceeds to support a commercial launch of ruvonoflast, suggesting a more measured view of timing and resources. For a young biotech, that shift is meaningful. It reflects a company still in development mode, not one ready to speak as though approval were imminent.
A second program remains in the background: trabzanoflast, another NLRP3 inhibitor optimized to enter the central nervous system. That compound has completed a phase 1 study, and Rezera wants to launch a phase 2 trial in neuroinflammatory conditions. Even so, the filing does not assume there will be enough capital to run that study to completion on existing funds alone. If proceeds exceed current estimates, the company expects to apply some of the additional money to that program.
The language is cautious for a reason. Cash allocation in a small biotech is not abstract bookkeeping; it determines whether a second asset advances or stalls.
A narrow workforce and a broad development ambition
Rezera has 21 full-time employees split between Boston and Cambridge, U.K., a lean structure for a company trying to move a vascular candidate into phase 3 while also maintaining a separate central nervous system program. That staffing level reinforces how concentrated the company’s near-term priorities are. The public offering is not about building a broad pipeline infrastructure. It is about financing a single cardiovascular thesis and preserving optionality for a second one.
The company’s rebrand from NodThera in September also fits the same pattern. The new identity is built around the anti-inflammatory rationale and the lead asset that now carries the most strategic weight. In biotech, naming changes often follow pipeline changes, and this one appears aligned with a more explicit push toward cardiovascular development.
PAD is a difficult indication in which to succeed because the therapeutic target is not simply stenosis but the inflammatory biology that drives chronic arterial damage. Rezera is betting that an NLRP3 inhibitor can address that layer of disease in a way current background therapy cannot. The phase 3 trial will need to show that the hypothesis is more than mechanistically elegant; it will need to produce clinically meaningful benefit in a population already managed with standard vascular prevention.
For now, the public offering will determine how quickly the company can test that premise. The real uncertainty is whether the phase 3 design, the patient population, and the inflammatory signal from earlier work will align closely enough to support a convincing cardiovascular readout in 2028.